UBS analyst Ashwani Verma raised the firm’s price target on Teva to $24 from $22 and keeps a Buy rating on the shares. The firm continues to be bullish on its Teva thesis going into the second half of 2024, and believes proceeds from the active pharmaceutical ingredients sale could be in the $4.8B-$6.8B range, with faster timing potentially resulting in quicker deleveraging, the analyst tells investors in a research note. UBS sees a potential beat and raise guidance on FY24 financials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- FTC sends Teva civil investigative demand over patents, WaPo reports
- Federal Court allows Vanda’s HETLIOZ patent lawsuit to proceed
- Teva announces data from fourth interim analysis of PEARL study of AJOVY
- Teva price target raised to $23 from $19 at Jefferies
- Teva’s agreement with the ITA has no impact on 2024 financial outlook